Source link : https://www.newshealth.biz/health-news/fmt-with-bezlotoxumab-in-ibd-patients-with-recurrent-cdi/
The addition of bezlotoxumab to fecal microbiota transplantation (FMT) does not provide any clear added benefit in patients with inflammatory bowel disease (IBD) and recurrent Clostridioides difficile infection (rCDI), according to a randomized controlled trial. “Given the high efficacy of FMT, the addition of bezlotoxumab may not provide a further reduction in CDI recurrence,” said study […]
Author : News Health
Publish date : 2024-11-11 13:01:45
Copyright for syndicated content belongs to the linked Source.